DIACCURATE

Endocrine-resistant metastatic breast tumor, glioblastoma, refractory acute myeloid leukemia, … to beat incurable cancers, Diaccurate explores the new frontiers of oncology in search of daring novel therapeutic approaches able to save lives. Now in the clinic, the French biotech is currently developing 3 proprietary therapeutics with novel mechanisms of action across several development programs: - DIACC3010, an optimized S6 Kinase inhibitor, highly selective oral antitumoral agent that crosses the blood-brain barrier - DIACC2010, a sole-in-class KIF20A kinesin inhibitor, a novel oncology target, IV antitumoral agent with high selectivity towards cancer cells -DIACC2020, antibody drug conjugate using DIACC2010 as payload Co-founded by Truffle Capital, Diaccurate has forged alliances with leaders in academia and industry, including Pasteur Institute, Paoli-Calmettes Institute (Marseille, France) and now Merck KGaA (Darmstadt, Germany). It relies on a high-level management team led by Dominique Bridon, PhD and a world-class Scientific Advisory Board chaired by Prof. Tasuku Honjo, recipient of the 2018 Nobel Prize in Medicine.